Clinical Trials
9 trialsNCT07349537 2026-06-01
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Revolution Medicines, Inc.
Phase 1 Recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT07300150 2026-05-07
A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors
PAQ Therapeutics, Inc.
Phase 1 Recruiting
NCT06835569 2026-05-06
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Alterome Therapeutics, Inc.
Phase 1 Recruiting
NCT05395052 2023-09-21
FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Phase 1 Terminated
NCT03319459 2021-11-22
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT00622674 2017-12-02
Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors
Masonic Cancer Center, University of Minnesota
Phase 1 Completed
NCT00397384 2015-09-30
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT00467116 2012-05-18
PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca
Vanderbilt-Ingram Cancer Center
Phase 1 Completed